Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer

References

• Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975–2017. Bethesda (MD): National Cancer Institute; 2020.
   Google Scholar
• VanderLaan PA, Rangachari D, Majid A, et al. Tumor biomarker testing in non-small-cell lung cancer: a decade of change. Lung Cancer. 2018;116:90–95.
   PubMed Web of Science ®Google Scholar
• Gregg JP, Li T, Yoneda KY. Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey. Transl Lung Cancer Res. 2019;8(3):286–301.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Non-small cell lung cancer treatment (PDQ®)-health professional version 2019. [cited 2019 Aug 6]. Available from: https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq
   Google Scholar
• Nellesen D, Dea K, Guerin A, et al. Reimbursement landscape for molecular testing in non-small cell lung cancer (NSCLC). AJMC. 2018;24(2):SP37–SP42.
   Google Scholar
• Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018;20(2):129–159.
   PubMed Web of Science ®Google Scholar
• Drilon A, Wang L, Arcila ME, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res. 2015;21(16):3631–3639.
   PubMed Web of Science ®Google Scholar
• Pennell NA, Arcila ME, Gandara DR, et al. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices. Am Soc Clin Oncol Educ Book. 2019;(39):531–542.
   PubMedGoogle Scholar
• Pennell NA, Mutebi A, Zhou Z-Y, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non-small-cell lung cancer using a decision analytic model. JCO Precis Oncol. 2019;3:1–9.
   PubMed Web of Science ®Google Scholar
• Dalal A, Guerin A, Mutebi A, et al. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer. J Med Econ. 2018;21(7):649–655.
   PubMed Web of Science ®Google Scholar
• Huang RSP, Severson E, Haberberger J, et al. Landscape of biomarkers in non-small cell lung cancer using comprehensive genomic profiling and PD-L1 immunohistochemistry. Pathol Oncol Res. 2021;27:592997.
   PubMed Web of Science ®Google Scholar
• Bruno DS, Hess LM, Li X, et al. Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(15_suppl):9005–9005.
   Web of Science ®Google Scholar
• Luk PP, Yu B, Ng CC, et al. BRAF mutations in non-small cell lung cancer. Transl Lung Cancer Res. 2015;4(2):142–148.
   PubMedGoogle Scholar
• Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol. 2016;34(7):721–730.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Health insurance coverage: early release of quarterly estimates from the national health interview survey, January–March 2020. National Center For Health Statistics; 2020. Available from: https://www.cdc.gov/nchs/data/nhis/earlyrelease/insur202108-508.pdf
   Google Scholar
• U.S. Census Bureau. Current population survey; 2018. Available from: https://www.census.gov/programs-surveys/cps.html
   Google Scholar
• Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–1640.
   PubMed Web of Science ®Google Scholar
• Badawy AA, Khedr G, Omar A, et al. Site of metastases as prognostic factors in unselected population of stage IV non-small cell lung cancer. Asian Pac J Cancer Prev. 2018;19(7):1907–1910.
   PubMedGoogle Scholar
• Al-Kateb H, Nguyen TT, Steger-May K, et al. Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS). Mol Oncol. 2015;9(9):1737–1743.
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Turner R, Chen YW, et al. Complications and economic burden associated with obtaining tissue for diagnosis and molecular analysis in patients with non-small-cell lung cancer in the United States. JOP. 2019;15(8):e717–e727.
   PubMedGoogle Scholar
• Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule. 2020. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSchedPayment/ClinicalLabFeeSched
   Google Scholar
• Cairns E. With its liquid biopsy approval, Foundation medicine takes on guardant 2020 [cited 2021 July 20]. Available from: https://www.evaluate.com/vantage/articles/analysis/spotlight/its-liquid-biopsy-approval-foundation-medicine-takes-guardant
   Google Scholar
• Centers for Medicare & Medicaid Services. Physician fee schedule. 2020. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched
   Google Scholar
• Dusetzina SB, Basch E, Keating NL. For uninsured cancer patients, outpatient charges can be costly, putting treatments out of reach. Health Aff (Millwood)). 2015;34(4):584–591.
   PubMed Web of Science ®Google Scholar
• Johnston KM, Sheffield BS, Yip S, et al. Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact. Curr Oncol. 2020;27(6):e569–e577.
   PubMed Web of Science ®Google Scholar
• Pisapia P, Pepe F, Baggi A, et al. Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: the KWAY Italian multicenter cost evaluation study. Crit Rev Oncol Hematol. 2022;169:103525.
   PubMed Web of Science ®Google Scholar
• Tan AC, Lai GGY, Tan GS, et al. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: incremental yield of actionable alterations and cost-effectiveness analysis. Lung Cancer. 2020;139:207–215.
   PubMed Web of Science ®Google Scholar
• Vigneswaran J, Tan YH, Murgu SD, et al. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. 2016;7(14):18876–18886.
   PubMedGoogle Scholar
• Fox KM, Brooks JM, Kim J. Metastatic non-small cell lung cancer: costs associated with disease progression. Am J Manag Care. 2008;14(9):565–571.
   PubMed Web of Science ®Google Scholar
• Freedman AN, Klabunde CN, Wiant K, et al. Use of next-generation sequencing tests to guide cancer treatment: results from a nationally representative survey of oncologists in the United States. JCO Precis Oncol. 2018;2:1–13.
   PubMed Web of Science ®Google Scholar
• Kaminski A, Szamreta EA, Shah R, et al. Barriers to next-generation sequencing despite increased utilization: U.S. physician survey results. J Clin Oncol. 2021;39(15_suppl):e18754–e18754.
   Web of Science ®Google Scholar
• Messner DA, Koay P, Al Naber J, et al. Barriers to clinical adoption of next-generation sequencing: a policy Delphi panel’s solutions. Per Med. 2017;14(4):339–354.
   PubMed Web of Science ®Google Scholar
• Gutierrez ME, Choi K, Lanman RB, et al. Genomic profiling of advanced non-small cell lung cancer in community settings: gaps and opportunities. Clin Lung Cancer. 2017;18(6):651–659.
   PubMed Web of Science ®Google Scholar
• Johnston KM, Sheffield BS, Yip S, et al. Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC). J Med Econ. 2020;23(10):1123–1129.
   PubMed Web of Science ®Google Scholar